| Literature DB >> 29166018 |
Paola Di Lello1, Richard Pastor1, Jeremy M Murray1, Robert A Blake1, Frederick Cohen1, Terry D Crawford1, Joy Drobnick1, Jason Drummond1, Lorna Kategaya1, Tracy Kleinheinz1, Till Maurer1, Lionel Rougé1, Xianrui Zhao1, Ingrid Wertz1, Chudi Ndubaku1, Vickie Tsui1.
Abstract
USP7 is a deubiquitinase implicated in destabilizing the tumor suppressor p53, and for this reason it has gained increasing attention as a potential oncology target for small molecule inhibitors. Herein we describe the biophysical, biochemical, and computational approaches that led to the identification of 4-(2-aminopyridin-3-yl)phenol compounds described by Kategaya ( Nature 2017 , 550 , 534 - 538 ) as specific inhibitors of USP7. Fragment based lead discovery (FBLD) by NMR combined with virtual screening and re-mining of biochemical high-throughput screening (HTS) hits led to the discovery of a series of ligands that bind in the "palm" region of the catalytic domain of USP7 and inhibit its catalytic activity. These ligands were then optimized by structure-based design to yield cell-active molecules with reasonable physical properties. This discovery process not only involved multiple techniques working in concert but also illustrated a unique way in which hits from orthogonal screening approaches complemented each other for lead identification.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29166018 DOI: 10.1021/acs.jmedchem.7b01293
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446